Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: INCB024360 Clear all
Withdrawn Phase 2 Interventional

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT03402880
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma
Interventions
Pembrolizumab, Epacadostat, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

NCT03374488
View directory record Official record
Conditions
UC (Urothelial Cancer)
Interventions
Pembrolizumab, Epacadostat, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
24
States / cities
Chandler, Arizona • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 2 Interventional Results available

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

NCT04586244
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 1 Interventional

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

NCT02559492
View directory record Official record
Conditions
Solid Tumors
Interventions
Itacitinib, Epacadostat, INCB050465
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Duarte, California • Denver, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

NCT01604889
View directory record Official record
Conditions
Melanoma
Interventions
Epacadostat, ipilimumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

NCT03358472
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

NCT03532295
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Epacadostat, Bevacizumab, Radiation therapy, Retifanlimab
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

NCT03602586
View directory record Official record
Conditions
Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
Interventions
Epacadostat, Pembrolizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
351
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 209 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 4, 2026, 6:47 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

NCT03325465
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 2 Interventional Results available

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

NCT03823131
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
ImmunoPulse, Epacadostat, Pembrolizumab, CORVax, Tavokinogene telseplasmid
Device · Drug · Biological
Lead sponsor
Chase Heaton, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 2 Interventional Results available

Epacadostat and Pembrolizumab in Patients With GIST

NCT03291054
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 4, 2026, 6:47 PM EDT
Not listed Phase 1 Interventional

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

NCT03217669
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer (NSCLC)
Interventions
Epacadostat, sirolimus
Drug
Lead sponsor
Chao Huang
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Fairway, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

NCT03260894
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC)
Interventions
Pembrolizumab, Epacadostat, Sunitinib, Pazopanib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 4, 2026, 6:47 PM EDT
Withdrawn Phase 2 Interventional

A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

NCT03238638
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

NCT02178722
View directory record Official record
Conditions
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
MK-3475, INCB024360
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
24
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

NCT03347123
View directory record Official record
Conditions
Solid Tumors
Interventions
Epacadostat, Nivolumab, Ipilimumab, Lirilumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 1 Interventional

A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies

NCT03471286
View directory record Official record
Conditions
Solid Tumor
Interventions
Epacadostat
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

NCT03493945
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
Interventions
M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat, Acetaminophen, Ibuprofen, Naproxen, Benadryl, EKG, Bone scan, CT chest, abdomen and pelvis, MRI
Biological · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 1 Interventional

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

NCT03707457
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Nivolumab, Anti-GITR Monoclonal Antibody MK-4166, IDO1 inhibitor INCB024360, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

NCT03361228
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB001158, Epacadostat, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

NCT02166905
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis, Pharmacological Study, Poly ICLC
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 4, 2026, 6:47 PM EDT
Terminated Phase 2 Interventional Results available

Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy

NCT03463161
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 4, 2026, 6:47 PM EDT
Withdrawn Phase 2 Interventional

A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma

NCT03310567
View directory record Official record
Conditions
Recurrent/ Metastatic Endometrial Carcinoma
Interventions
Epacadostat + pembrolizumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 4, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

NCT03322540
View directory record Official record
Conditions
Lung Cancer
Interventions
Pembrolizumab, Epacadostat, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Anaheim, California • Whittier, California • Fort Myers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 4, 2026, 6:47 PM EDT